Pacira BioSciences Inc [PCRX] stock is trading at $26.29, up 2.18%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PCRX shares have gain 9.59% over the last week, with a monthly amount glided 10.18%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Pacira BioSciences Inc [NASDAQ: PCRX] stock has seen the most recent analyst activity on December 09, 2025, when Barclays initiated its Equal Weight rating and assigned the stock a price target of $27. On July 25, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $30 on the stock. Truist upgraded its rating to a Hold and increased its price target to $25 on January 30, 2025. Truist downgraded its rating to a Sell and reduced its price target to $8 on August 13, 2024. RBC Capital Mkts downgraded its rating to Sector Perform for this stock on August 12, 2024, and downed its price target to $14. In a note dated August 12, 2024, Raymond James downgraded an Mkt Perform rating on this stock.
Pacira BioSciences Inc [PCRX] stock has fluctuated between $18.17 and $27.64 over the past year. Currently, Wall Street analysts expect the stock to reach $27 within the next 12 months. Pacira BioSciences Inc [NASDAQ: PCRX] shares were valued at $26.29 at the most recent close of the market. An investor can expect a potential return of 2.7% based on the average PCRX price forecast.
Analyzing the PCRX fundamentals
Pacira BioSciences Inc [NASDAQ:PCRX] reported sales of 716.79M for the trailing twelve months, which represents a growth of 6.49%. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at 0.06%, Pretax Profit Margin comes in at 0.06%, and Net Profit Margin reading is 0.04%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.04 and Total Capital is 0.03. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.48 points at the first support level, and at 24.68 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.78, and for the 2nd resistance point, it is at 27.27.
Ratios To Look Out For
For context, Pacira BioSciences Inc’s Current Ratio is 5.26. Also, the Quick Ratio is 3.78, while the Cash Ratio stands at 1.38. Considering the valuation of this stock, the price to sales ratio is 1.58, the price to book ratio is 1.55 and price to earnings (TTM) ratio is 58.93.
Transactions by insiders
Recent insider trading involved Cross Shawn, Chief Financial Officer, that happened on Dec 09 ’25 when 15896.0 shares were sold. Chief Financial Officer, Cross Shawn completed a deal on Dec 10 ’25 to sell 9104.0 shares. Meanwhile, Officer Cross Shawn bought 9104.0 shares on Dec 10 ’25.
